UY34603A - Anticuerpos anti-asic-1 y usos de los mismos - Google Patents

Anticuerpos anti-asic-1 y usos de los mismos

Info

Publication number
UY34603A
UY34603A UY34603A UY34603A UY34603A UY 34603 A UY34603 A UY 34603A UY 34603 A UY34603 A UY 34603A UY 34603 A UY34603 A UY 34603A UY 34603 A UY34603 A UY 34603A
Authority
UY
Uruguay
Prior art keywords
asic
antibodies
same
figura
hay
Prior art date
Application number
UY34603A
Other languages
English (en)
Inventor
Mcdonald Lynn
Gao Min
Marc R Morra
Nicole M Alessandri Haber
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34603(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY34603A publication Critical patent/UY34603A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente a células que expresan el canal iónico sensible al ácido de tipo 1 (ASIC1). De acuerdo con ciertas realizaciones de la invención, los anticuerpos inhiben las corrientes iónicas mediadas por ASIC1, inducidas por ácido en células que expresan ASIC1 humana. Los anticuerpos de la invención son útiles para el tratamiento del dolor, incluyendo el dolor asociado con intervenciones q uirúrgicas y diversas enfermedades y trastornos.
UY34603A 2012-01-31 2013-01-31 Anticuerpos anti-asic-1 y usos de los mismos UY34603A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
UY34603A true UY34603A (es) 2013-07-31

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
UY34603A UY34603A (es) 2012-01-31 2013-01-31 Anticuerpos anti-asic-1 y usos de los mismos

Country Status (33)

Country Link
US (3) US9150648B2 (es)
EP (2) EP2809681B1 (es)
JP (1) JP6302844B2 (es)
KR (1) KR102111941B1 (es)
CN (1) CN104093738B (es)
AR (1) AR089852A1 (es)
AU (1) AU2013215254B2 (es)
CA (1) CA2862332C (es)
CL (1) CL2014002019A1 (es)
CO (1) CO7020877A2 (es)
CY (2) CY1121368T1 (es)
DK (2) DK2809681T3 (es)
EA (1) EA028647B1 (es)
ES (2) ES2886123T3 (es)
HR (2) HRP20190358T1 (es)
HU (2) HUE042531T2 (es)
IL (2) IL233410A0 (es)
IN (1) IN2014CN04645A (es)
JO (1) JO3547B1 (es)
LT (2) LT2809681T (es)
MX (1) MX358518B (es)
MY (1) MY168748A (es)
NZ (1) NZ626242A (es)
PH (1) PH12014501613B1 (es)
PL (2) PL3453723T3 (es)
PT (2) PT2809681T (es)
RS (2) RS58439B1 (es)
SG (1) SG11201403222UA (es)
SI (2) SI3453723T1 (es)
SM (1) SMT202100628T1 (es)
TW (1) TWI591073B (es)
UY (1) UY34603A (es)
WO (1) WO2013116296A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2886123T3 (es) 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
JP2017513854A (ja) 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
PT3248986T (pt) 2014-05-16 2022-04-05 Ablynx Nv Domínios variáveis de imunoglobulina
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
IL276164B2 (en) * 2018-01-26 2024-11-01 Regeneron Pharma Anti-tmprss2 antibodies and antigen-binding fragments
KR20220016891A (ko) * 2019-06-04 2022-02-10 상하이테크 유니버시티 친화성-성숙된 항-ASIC1a 항체
PH12022550056A1 (en) * 2019-07-11 2023-04-12 Memorial Sloan Kettering Cancer Center Dll3-targeting antibodies and uses thereof
WO2021012176A1 (en) * 2019-07-23 2021-01-28 Shanghaitech University Asic1 channel antagonist antibody
AU2020346886A1 (en) * 2019-09-13 2022-04-14 Memorial Hospital For Cancer And Allied Diseases Anti-CD371 antibodies and uses thereof
CA3228654A1 (en) * 2021-08-09 2023-02-16 Brian Rabinovich Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
CN118159558A (zh) * 2021-09-02 2024-06-07 纪念斯隆-凯特琳癌症中心 抗dll3抗体和其用途
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
CA2308014A1 (en) 1997-10-29 1999-05-06 Mcgill University Dna encoding a human proton-gated ion channel and uses thereof
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
MXPA04009418A (es) * 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070092444A1 (en) * 2003-09-11 2007-04-26 The Uab Research Foundation Inhibition of inward sodium currents in cancer
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
WO2006038070A2 (en) 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
HRP20110859T1 (hr) * 2004-12-21 2011-12-31 Medimmune Limited Protutijela usmjerena na angiopoietin-2 i njihova upotreba
NZ562234A (en) * 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
WO2008007131A2 (en) * 2006-07-14 2008-01-17 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DE602008002913D1 (de) 2007-04-03 2010-11-18 Ilegusavnid Genetics Resource Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2853897A1 (en) * 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
EP2356270B1 (en) * 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
ES2886123T3 (es) 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Also Published As

Publication number Publication date
CN104093738A (zh) 2014-10-08
IL233410A0 (en) 2014-08-31
EP2809681B1 (en) 2018-12-05
CN104093738B (zh) 2018-05-18
KR20140125363A (ko) 2014-10-28
HUE056335T2 (hu) 2022-02-28
JP2015508063A (ja) 2015-03-16
DK2809681T3 (en) 2019-03-11
PL3453723T3 (pl) 2022-01-03
AR089852A1 (es) 2014-09-24
BR112014018651A2 (pt) 2017-07-04
MX358518B (es) 2018-08-24
IL254416A0 (en) 2017-11-30
PH12014501613A1 (en) 2014-10-13
HRP20211541T1 (hr) 2021-12-24
LT3453723T (lt) 2021-09-10
MY168748A (en) 2018-11-30
TWI591073B (zh) 2017-07-11
US20180222976A1 (en) 2018-08-09
US20130195878A1 (en) 2013-08-01
US9150648B2 (en) 2015-10-06
HRP20190358T1 (hr) 2019-04-05
EP3453723B1 (en) 2021-08-11
IL254416B (en) 2018-03-29
PT2809681T (pt) 2019-02-18
ES2707599T3 (es) 2019-04-04
JO3547B1 (ar) 2020-07-05
SI2809681T1 (sl) 2019-04-30
IN2014CN04645A (es) 2015-09-18
EP3453723A3 (en) 2019-04-10
JP6302844B2 (ja) 2018-03-28
SMT202100628T1 (it) 2022-01-10
KR102111941B1 (ko) 2020-05-18
HK1199269A1 (en) 2015-06-26
EP3453723A2 (en) 2019-03-13
AU2013215254A1 (en) 2014-07-03
CL2014002019A1 (es) 2015-01-16
CA2862332C (en) 2021-05-18
EP2809681A1 (en) 2014-12-10
MX2014008541A (es) 2014-10-24
SI3453723T1 (sl) 2021-11-30
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
TW201335182A (zh) 2013-09-01
WO2013116296A1 (en) 2013-08-08
HUE042531T2 (hu) 2019-07-29
PL2809681T3 (pl) 2019-05-31
DK3453723T3 (da) 2021-09-13
PT3453723T (pt) 2021-09-07
US20160002332A1 (en) 2016-01-07
RS58439B1 (sr) 2019-04-30
ES2886123T3 (es) 2021-12-16
CY1121368T1 (el) 2020-05-29
US10513557B2 (en) 2019-12-24
RS62454B1 (sr) 2021-11-30
AU2013215254B2 (en) 2017-08-31
PH12014501613B1 (en) 2014-10-13
NZ626242A (en) 2017-02-24
SG11201403222UA (en) 2014-07-30
EA201491452A1 (ru) 2014-11-28
CY1124778T1 (el) 2022-11-25
CA2862332A1 (en) 2013-08-08
LT2809681T (lt) 2019-02-11

Similar Documents

Publication Publication Date Title
FR22C1048I2 (fr) Anticorps anti-cd3 et méthodes d'utilisation
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
UY34538A (es) Heteroarilos y usos de los mismos
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
SMT201700003B (it) Didropiridoni come inibitori del fattore xia
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
MX364714B (es) Animales no humanos geneticamente modificados y metodos de uso de los mismos.
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
BR112014026926A2 (pt) uso terapêutico de produtos de semente de chardonnay

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220104